patent.fyi
Applications  /  US 2026/0355368
United States Patent Application Publication

US 2026/0355368 A1

Published
Nov 12, 2026
Filed
May 31, 2024
Earliest date on the face
May 31, 2023
Classification
A61K 51/1096
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Glycan attachment by cycloaddition

What ifWhat if the attachment linker carried a strained cyclooctyne that coupled to an azide on the antibody glycan?
Claim language“a thiol-reactive group or an amine-reactive group”

Enzymatic glycan remodeling places an azide on the antibody's Fc carbohydrate. The strained cyclooctyne reacts with the azide in aqueous buffer to form a covalent triazole linkage.

1.1Conjugation at separate antibody sites

What ifWhat if the antibody carried the effector and the potency enhancing moiety at two separate sites through independent linear linkers?
Claim language“a branching group which is at least trivalent”

An engineered cysteine forms a thioether with a maleimide-bearing effector linker. An azide on the Fc glycan couples to a cyclooctyne-bearing potency enhancing moiety, so the antibody itself carries both attachments.

1.2Direct radioiodination of the branch

What ifWhat if the effector attached directly to an aromatic carbon of the branching group?
Claim language“conjugated to T via a linker LE”

The branching group incorporates an activated phenolic ring with a free carbon adjacent to the hydroxyl group. Electrophilic radioiodination forms a direct carbon–iodine bond at that position, and iodine-131 supplies the beta emission.

1.2Uptake imaging as dose feedback

What ifWhat if the secondary branch carried an imaging reporter and the treatment team used measured tumor uptake to set the administered activity?
Claim language“a potency enhancing moiety”

A near-infrared fluorophore on the secondary branch reports the location of the conjugate in an optically accessible tumor. In a superficial tumor model, calibrated fluorescence measured at a fixed interval after a tracer dose estimates uptake and informs the activity selected for a subsequent therapeutic dose.

1.3Separate dosing of a sensitizer

What ifWhat if a separately administered radiosensitizer enhanced the effect of the radiolabeled conjugate?
Claim language“A is conjugated to T via a linker LA”

A small-molecule inhibitor of DNA damage repair circulates independently of the tumor-targeting radioconjugate. Dosing overlaps inhibitor exposure with tumor irradiation, reducing repair of radiation-induced DNA lesions during that interval.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Fluorescent tracer for water residue testing

An atrazine-binding antibody fragment attaches through an engineered cysteine to a trivalent hub bearing a red fluorophore and a short polyethylene glycol chain on separate arms. The fluorophore provides the readout, and the polyethylene glycol chain reduces adsorption of the tracer to the assay surface. The tracer binds to immobilized atrazine analog in a microplate, while dissolved atrazine in the sample competes for the same binding site. Fluorescence after washing decreases as the atrazine concentration increases.

Component substitution

Aminooxy attachment to antibody glycans

An aminooxy group replaces the thiol-reactive or amine-reactive group on the antibody attachment arm of the trivalent hub. Mild periodate oxidation converts vicinal diols on the antibody Fc glycans into aldehydes that react with the aminooxy group to form oxime bonds. Separate arms carry a near-infrared fluorophore and a hydrophilic polyethylene glycol chain that limits aggregation of the dye-bearing conjugate during imaging.

Trimesic acid as the branching hub

Benzene-1,3,5-tricarboxylic acid replaces the amino-acid-based branching group and supplies three carboxyl attachment sites. A monoester intermediate and stepwise coupling of the remaining carboxyl groups install an amine-terminated fluorophore spacer and an amine-terminated polyethylene glycol chain as amides. Hydrolysis of the remaining ester exposes the third carboxyl group for coupling to a maleimide-bearing spacer, which reacts with a cysteine on the targeting antibody fragment. The antibody fragment directs the fluorophore to antigen-bearing cells, and the polymer chain limits dye-driven association in aqueous buffer.

Parameter or scale variation

Defined spacer lengths for cell labeling

Three conjugates share a tumor-antigen-binding antibody fragment, a trivalent hub, a red fluorophore, and a sulfobetaine group that reduces nonspecific adsorption. The fluorophore arm contains a discrete polyethylene glycol spacer of 4, 12, or 24 ethylene oxide units, and the other two arms have fixed compositions. Antigen-positive and antigen-negative cells receive each conjugate at 10 nanomolar for 30 minutes under identical staining conditions. Flow cytometry measures the fluorescence ratio between the two cell populations for each spacer length.

Combination with existing systems

Conjugate labeling in spectral flow cytometry

A tumor-antigen-binding antibody attaches to one arm of a trivalent hub, with a far-red fluorophore and a short hydrophilic polymer attached to separate arms. The polymer improves the aqueous dispersibility of the dye-bearing reagent. A spectral flow cytometer records the emission profile of cells stained with the conjugate alongside other fluorescent markers. Software uses a single-stain reference acquired with the assembled conjugate to calculate its contribution to each cell's emission spectrum.

Automated or data-driven variant

Automated selection of conjugate formulations

A liquid handler assembles a panel of trivalent conjugates from a common antibody fragment and fluorophore with one hydrophilic modifier per hub. The panel varies modifier identity and attachment spacer length while holding the antibody and fluorophore constant. Automated size-exclusion chromatography measures monomer fraction, and an imaging plate reader measures fluorescence in matched antigen-positive and antigen-negative cell wells. Software ranks formulations by the fluorescence ratio among candidates with at least 95 percent monomer.

Specific version of a part

Irradiation from an external source

A positron-emitting tracer on the antibody conjugate maps uptake in the tumor. The resulting image is registered to a planning scan, and a collimated photon beam delivers the prescribed dose to the treatment volume.

Three arms on one lysine

A lysine residue provides three attachment sites through its alpha amine, side-chain amine, and carboxyl group. Selective protection of the two amines allows sequential installation of distinct arms for antibody attachment, effector attachment, and potency enhancement.

Maleimide coupling to antibody cysteine

The antibody attachment linker ends in a maleimide that reacts with a solvent-accessible cysteine near neutral pH. Thiol addition produces a covalent thioether linkage.

Radiometal chelator on a spacer

A short polyethylene glycol spacer links a tetraazamacrocyclic chelator to the branching group through covalent amide bonds. The chelator coordinates lutetium-177, whose beta emissions deliver the radiation dose.

Albumin binding through a spacer

An amide-linked polyethylene glycol spacer joins the branching group to an aryl albumin-binding moiety. Reversible binding to circulating albumin extends blood residence and increases the time available for tumor uptake.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2012/0201809 A1
Published
Aug 9, 2012
Filed
Nov 28, 2011
Class
A61K 39/395
Document BUS 10,406,229 B2
Published
Sep 10, 2019
Filed
Mar 2, 2017
Class
A61K 45/06
Claim 1
Document A
Document B
1.1a structure of formula (I-X): wherein: (1) LZ(i) is a linker comprising a thiol-reactive group or an amine-reactive group, (2) T is a branching group which is at least trivalent, (3) E is an effector moiety
The present invention relates to Multifunctional Antibody Conjugates, comprising an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CLκ) comprising K188 according to Kabat numbering; a linker comprising the formula X-Y-Z, wherein Z is a group is covalently connected to the antibody through the side chain of K188, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently c
A · US 2012/0201809 A1 · abstract
1.2wherein E is conjugated to T via a linker LE, and (4) A is a potency enhancing moiety
In some aspects of the invention, the linker may comprise the formula: -X-Y-Z-; wherein X is the attachment group to the Effector Moiety (for example, via a peptide-linking residue), Y is a spacer region, and Z is an attachment moiety to the side chain of a lysine or cysteine residue on an antibody (for example, an anti-IGF1R antibody).
A · US 2012/0201809 A1 · ¶ 86
1.3wherein A is conjugated to T via a linker LA.
In still other embodiments, the methods comprise administering a composition comprising at least three D-peptides and at least one potency-enhancing cargo linked to a multimer scaffold wherein the at least one potency-enhancing group is linked to the multimer scaffold via a fourth orthogonal group with a PEG linker.
B · US 10,406,229 B2 · ¶ 156

An empty cell means only that no passage was reproduced there.

Statements in these documents
Targeting both IGF1R and Ang2 in the same therapy may prove to be an effective tool for oncologists to use in multiple treatment settings.
A · US 2012/0201809 A1 · ¶ 5
There therefore exists a need to provide alternative oncology therapies targeting both IGR-1R and Ang2.
A · US 2012/0201809 A1 · ¶ 5
According to this model, an inhibitor that binds to the N-trimer and prevents hairpin formation can inhibit viral entry.
B · US 10,406,229 B2 · ¶ 6
What is needed in the art are peptides with suitable pharmacokinetic properties that can inhibit the entry of gp41 into cells.
B · US 10,406,229 B2 · ¶ 6
Cite aspatent.fyi, US 2026/0355368 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355368/, SHA-256 3539a0235d65ec21ab282cecc88332706ce6e44e1ab5e4100250259ca1aa6161
First published
Permanent addresshttps://patent.fyi/US20260355368/
Content fingerprint (SHA-256)3539a0235d65ec21ab282cecc88332706ce6e44e1ab5e4100250259ca1aa6161
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi